Member Info for magmanus_49

Excellent Hedge. This RNS and its sigficance has also been completly missed by PI's.

BI is about o pay off handsomely and now they are looking to secure Remote Monitored Systems plc. CEO Trevor Brown is smart cookie and is CEO few other medical companies and is an expert in thsi feild. He also owns 43Mill shares. He will make this happen. Right now he is doing due-diligence on upcomming Stonechecker sale, and as soonas they finish with thsi he and his management team should comeplete this major acquisition.

There is muhc more to IQAI and Investors are just starting to realise - it has been oversold over the years. Last placing was 10p, and last year 16p. And now with 3 pieces of game changing and money making events - fully expect it to be over 16p.

For now we can expect and buy towards 11-13p. Well done for highlightig this one.

Inknow current re-rate is for Stonechescker sale/rolayties. But don't forget this one, next on major impact to the bottom line.

In November 2019, IQ-AI announced the addition of IB Stroke to its product roadmap. As a logical extension of its current portfolio of proven neuro products, IB Stroke has the advantage of leveraging existing FDA cleared and CE marked algorithms to rapidly generate information commonly used in the diagnosis of stroke in patients. The team at IQ-AI's subsidiary, Imagining Biometrics ("IB") is pleased to announce that the development of IB Stroke is on track. In addition, a subcommittee of the USA Jumpstarting Brain Tumour Drug Development Coalition has recently recommended that the quantitative perfusion capability, exclusive to IB, provides a singular foundation upon which to build IB Stroke and is now the consensus recommended standard for the National Clinical Trials Network.

The technology will first be made available as part of a streamlined workflow within IB Rad Tech and is on target to be released in early Q4!

IB recently passed their annual ISO 13485:2016 recertification audit; an international quality standard and pre-requisite for European distribution.

IB stroke has had recent circa $2.6m development input - so expect it to be sold for multiple of this figure as they complete the final checks. My guess will first go to the new global medical group....as hinted in the last statement/ update in the company.

And there are few more in the piple-line.

IQAI has been a sleeping beuty for a year, oversold abd forgetton, and now just waking up.

Closed high of the day on Friday - and was total NT at 5.20p. Tired 5.30 and nothing - buy order just expired.

No one is selling, only mms games for the last 2 days - based on the facts and current pipeline, and pending sale of FDA approved product/ business to a major international medical group. I see this as mojor turnaround for the company, and their stratetgy is about to pay off big time.

Also believe this one deal, will lead to many others with the same major company and others around the world.

Was 16p last year - without the upcomming deal. It hit 16p only on hope. And now its much closer to actually happening. So why is the price still 5/6p. Thats why you can't buy in size, and it goes NT every 3o mins.

I will stay put and add. Thank you very much.

SOme veyr goofd info Dbox.

Therfore, the company has $5M+ cash in grant money ($2.8m at back end of 2019 + $2.6m awarded in June 2020. And the compnay has stated on Friday update ''These are both NIH grants and together cover "60% of the development cost of IB" at current staffing''

They have nealry £1m cash and very low burn - and now looking for major sale and royaltie on FDA approved product. Finally, some payoff. Gald I am invested in.

Also noted i could not but at 5.20p or 5.30p on close? Was total NT, but you could sell as much as you like.

My target 11-13p in the short term before anything else. Just too much demand and not enough sellers - especially after 2 days mm raids to take out all stops etc.